Compare GAME & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | VERU |
|---|---|---|
| Founded | 2011 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 41.7M |
| IPO Year | 2024 | 1996 |
| Metric | GAME | VERU |
|---|---|---|
| Price | $0.32 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 1.1M | 75.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $96,198,101.00 | $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 85.00 | N/A |
| 52 Week Low | $0.26 | $0.36 |
| 52 Week High | $2.87 | $4.59 |
| Indicator | GAME | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 54.12 |
| Support Level | $0.27 | $2.15 |
| Resistance Level | $0.33 | $2.80 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 56.59 | 69.92 |
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.